146 related articles for article (PubMed ID: 29152077)
1. Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA
Kim HR; Cha YJ; Hong MH; Gandhi M; Levinson S; Jung I; Lee JG; Lee CY; Cho BC; Ha SJ; Shim HS
Oncotarget; 2017 Oct; 8(50):87234-87243. PubMed ID: 29152077
[TBL] [Abstract][Full Text] [Related]
2. Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Coppock JD; Volaric AK; Mills AM; Gru AA
Hum Pathol; 2018 Dec; 82():282-288. PubMed ID: 30075155
[TBL] [Abstract][Full Text] [Related]
3. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.
Takamori S; Toyokawa G; Okamoto I; Takada K; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Mukae N; Hirai F; Tagawa T; Oda Y; Iwaki T; Iihara K; Nakanishi Y; Maehara Y
Anticancer Res; 2018 Jan; 38(1):553-557. PubMed ID: 29277823
[TBL] [Abstract][Full Text] [Related]
5. Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
Kitazono S; Fujiwara Y; Tsuta K; Utsumi H; Kanda S; Horinouchi H; Nokihara H; Yamamoto N; Sasada S; Watanabe S; Asamura H; Tamura T; Ohe Y
Clin Lung Cancer; 2015 Sep; 16(5):385-90. PubMed ID: 25937270
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Utility of PD-L1 Expression in Lung Adenocarcinoma: Immunohistochemistry and RNA In Situ Hybridization.
Gafeer MM; Hosny Mohammed K; Ormenisan-Gherasim C; Choudhary F; Siddiqui MT; Cohen C
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):e86-e90. PubMed ID: 28968265
[TBL] [Abstract][Full Text] [Related]
7. [Heterogeneity in PD-L1 expression on infiltrating immune cells between the primary and metastatic breast cancers].
Wang XR; Zhang NN; Lyu F; Wang HL; Liu YP
Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):430-434. PubMed ID: 32392925
[No Abstract] [Full Text] [Related]
8. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
Sheffield BS; Fulton R; Kalloger SE; Milne K; Geller G; Jones M; Jacquemont C; Zachara S; Zhao E; Pleasance E; Laskin J; Jones SJ; Marra MA; Yip S; Nelson BH; Gown AM; Ho C; Ionescu DN
J Histochem Cytochem; 2016 Oct; 64(10):587-600. PubMed ID: 27591097
[TBL] [Abstract][Full Text] [Related]
9. Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples.
Soo RA; Yun Lim JS; Asuncion BR; Fazreen Z; Herrera MC; Mohd Omar MF; Diem Phuong NH; Seet JE; Amanuel B; Iacopetta B; Byrne D; Hendry S; Fox S; Soong R
Oncotarget; 2018 Jan; 9(6):6841-6851. PubMed ID: 29467933
[TBL] [Abstract][Full Text] [Related]
10. Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort.
Jin Y; Shen X; Pan Y; Zheng Q; Chen H; Hu H; Li Y
J Thorac Dis; 2019 Nov; 11(11):4591-4601. PubMed ID: 31903248
[TBL] [Abstract][Full Text] [Related]
11. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
Igawa S; Sato Y; Ryuge S; Ichinoe M; Katono K; Hiyoshi Y; Otani S; Nagashio R; Nakashima H; Katagiri M; Sasaki J; Murakumo Y; Satoh Y; Masuda N
Oncology; 2017; 92(5):283-290. PubMed ID: 28222447
[TBL] [Abstract][Full Text] [Related]
12. Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer.
Kumar M; Guleria B; Swamy S; Soni S
Lung India; 2020; 37(2):145-150. PubMed ID: 32108600
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.
Kim S; Koh J; Kwon D; Keam B; Go H; Kim YA; Jeon YK; Chung DH
Eur J Cancer; 2017 Apr; 75():141-149. PubMed ID: 28222308
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study.
Kim H; Kwon HJ; Park SY; Park E; Chung JH
Oncotarget; 2017 Nov; 8(58):98524-98532. PubMed ID: 29228707
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Cancer Immunol Immunother; 2017 Jul; 66(7):865-876. PubMed ID: 28341875
[TBL] [Abstract][Full Text] [Related]
16. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
[TBL] [Abstract][Full Text] [Related]
17. Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer.
Pang C; Yin L; Zhou X; Lei C; Tong R; Huang M; Gong Y; Ding Z; Xue J; Zhu J; Wang Y; Ren L; Zhou L; Wang J; Peng F; Zhou Q; Lu Y
J Thorac Dis; 2018 Feb; 10(2):816-824. PubMed ID: 29607153
[TBL] [Abstract][Full Text] [Related]
18. Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer.
Chen Q; Fu YY; Yue QN; Wu Q; Tang Y; Wang WY; Wang YS; Jiang LL
Int J Clin Exp Pathol; 2019; 12(3):774-786. PubMed ID: 31933885
[TBL] [Abstract][Full Text] [Related]
19. Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.
Yuan J; Zhang J; Zhu Y; Li N; Tian T; Li Y; Li Y; Li Z; Lai Y; Gao J; Shen L
Oncotarget; 2016 Jun; 7(26):39671-39679. PubMed ID: 27191996
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis.
Shen X; Wang Y; Jin Y; Zheng Q; Shen L; Chen Y; Li Y
J Thorac Dis; 2021 Jul; 13(7):4360-4370. PubMed ID: 34422362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
